Navidea Biopharmaceuticals News

0,1549 $ +1,24% +0,0019 $
In : 0,1381 € | 15:31:56 Uhr AMEX | Mehr Kurse »
ISIN: US63937X1037
US-Symbol: NAVB
Typ: Aktie

Navidea Biopharmaceuticals News

Fr Navidea Biopharmaceuticals Announces Reverse Stock Split Businesswire
08.04.19 Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates Businesswire
02.04.19 Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting Businesswire
22.03.19 Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates Businesswire
07.03.19 Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Businesswire
28.02.19 Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update Businesswire
01.02.19 Navidea Biopharmaceuticals Announces Extension of NYSE American Listing Businesswire
24.01.19 Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court Businesswire
11.04.14 Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc. PR Newswire
13.08.13 Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc. PR Newswire
03.06.13 SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc. PR Newswire
11.09.12 Navidea Biopharmaceuticals-​Aktie: "buy" - Ladenburg Thalmann Aktiencheck
11.09.12 Navidea Biopharmaceuticals-​Aktie: Kursziel gesenkt - Rodman & Renshaw Aktiencheck
22.08.12 Navidea Biopharmaceuticals-​Aktie: "buy" - ThinkEquity Partners Aktiencheck
31.07.12 Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. PR Newswire
23.07.12 Navidea Biopharmaceuticals-​Aktie: vielversprechende Pipeline - Hot Stocks Investor Aktiencheck




14:17 Uhr +3,43%
flatExperte Volaric: "Das sind die Gründe für den Platin- und den Öl-​Anstieg"